Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis-Reference-Cited by-同舟云学术

Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis

Published:2023-12-25 Issue:6 Volume:101 Page:74-80
ISSN:2542-1506
Container-title:Tuberculosis and Lung Diseases
language:
Short-container-title:Tuberk. bolezni lëgk.

Author:

Solodovnikova V. V.¹,Skryagin A. E.²,Isaykina Y. I.³,Klimuk D. A.¹,Gurevich G. L.¹,Skryagina E. M.¹

Affiliation:

1. Republican Scientific and Practical Center of Pulmonology and Phthisiology

2. Belarusian State Medical University

3. Republican Scientific and Practical Center of Children's Oncology, Hematology and Immunology

Abstract

The objective: to evaluate the effectiveness of treatment with autologous mesenchymal stromal cells (MSCs) in patients with drug resistant pulmonary tuberculosis (DR TB).Subjects and Methods. 120 patients with drug resistant tuberculosis aged 18 to 61 years old were enrolled in the study. They all were treated at the Republican Scientific and Practical Center of Pulmonology and Phthisiology from 2009 to 2018. Against the background of anti-tuberculosis treatment, patients (60 people) from Main Group (MG) underwent bone marrow sampling and then intravenous administration of autologous MSCs.Results. The average dose of administered cells was 1x106 per kg of the patient body weight. The average duration of MSC cultivation made 35 days. Treatment effectiveness in MG made 90% versus 71% in Control Group (CG). All patients who were successfully cured of tuberculosis (TB) using autologous MSCs had no tuberculosis relapses during 5 years of follow-up. In Control Group, 8 (19%) cases of relapse were reported. In Main Group versus Comparison Group, the rates indicating healing of cavities and absence of relapse are statistically significantly better.Conclusion. The use of autologous MSCs in patients with drug resistant tuberculosis has shown its high effectiveness.

Publisher

LLC "Medical Knowledge and Technologies"

Subject

General Medicine

Reference10 articles.

1. Caplan A., Dennis J.E. Mesenchymal stem cells as trophic mediators // J. Cell Biochem. – 2006. – Vol. 98, №5, P. – 1076–1084.

2. Chow L., Johnson V., Impastato R., et al. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells // Stem Cells Transl. Med. –2019. – Vol. 9, №2, P. – 235–249.

3. Furin J., Cox H., Pai M. Tuberculosis // Lancet. – 2019. – Vol. 393. – P. 1642-1656.

4. Global tuberculosis report 2022. – Geneva: World Health Organization, 2022. – P. 68.

5. Korbling M., Estrov Z. Adult stem cells fo rtissue repair − a new therapeutic concept // N. Engl. J. Med. – 2003. – Vol. 349, № 6. – P. 570-582.